Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088979 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Phase 2 study of Thyroid Eye Disease, sponsored by Tourmaline Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 20
- Study locations
NCT06088979 is a Phase 2 study of Thyroid Eye Disease that is actively recruiting participants, run by Tourmaline Bio. The registered enrollment target is 81 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06088979, a Phase 2 study of Thyroid Eye Disease, is actively recruiting participants, sponsored by Tourmaline Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TOUR006 - 20 MG
- DRUG TOUR006 - 50 MG
Study Locations (20)
California
- Headlands Research - AMCR - Site 840-131 - Escondido
- Foothill Eye Institute - Site 840-116 - Pasadena
- University of California Davis Eye Center - Site 840-119 - Sacramento
- Cockerham Eye Consultants - Site 840-114 - San Diego
- The Pacific Center for Oculofacial and Aesthetic Plastic Surgery - Site 840-122 - San Francisco
Florida
- Bascom Palmer Eye Institute - Site 840-115 - Miami
- Cordova Research Institute - Site 840-103 - Miami
- Aran Eye Associate - Sweetwater
Michigan
- W.K. Kellogg Eye Center - Site 840-126 - Ann Arbor
- Michigan State University - Site 840-127 - East Lansing
- Kahana Oculoplastic and Orbital Surgery - Site 840-112 - Livonia
Arizona
- Catalina Eye Care - Site 840-121 - Tucson
Colorado
- UC Hospital Sue Anschulz-Rodgers Eye Center - Site 840-101 - Aurora
Kentucky
- University of Louisville Health Eye Institute - Site 840-108 - Louisville
Massachusetts
- Ophthalmic Consultants of Boston - Site 840-128 - Boston
Minnesota
- Mayo Clinic - Site 840-102 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06088979
The ClinicalTrials.gov registry entry for NCT06088979 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (20% lower). The listed sponsor is Tourmaline Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06088979 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06088979 about?
NCT06088979 is a clinical study titled "A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease". Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
What is the current status of trial NCT06088979?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2024-02-19. Estimated completion is 2027-09.
What conditions does trial NCT06088979 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06088979?
The interventions under investigation include: Placebo (OTHER), TOUR006 - 20 MG (DRUG), TOUR006 - 50 MG (DRUG).
Who is sponsoring clinical trial NCT06088979?
This trial is sponsored by Tourmaline Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088979 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
Anti-VEGF Therapy for Acute Thyroid Eye Disease
COMPLETED · Phase 2
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.